Published online before print October 27, 2005, doi: 10.1161/01.STR.0000190118.02275.33
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:2748.)
© 2005 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke
A Systematic Review and Meta-Analysis
From the Université Paris-Descartes, Faculté de Médecine, Department of Neurology, Hôpital Sainte-Anne (E.T., J.L.M.); Department of Cardiology, Hôpital Cochin (O.V.); Department of Biostatistics, Hôpital Européen Georges Pompidou, (G.C., S.P.); and Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK (P.M.R.).
Correspondence to Dr Emmanuel Touzé, Université Paris-Descartes, Faculté de Médecine, Service de Neurologie, Hôpital Sainte-Anne, 1 rue Cabanis, 75674 Paris Cedex 14. E-mail e.touze{at}ch-sainte-anne.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Whether stroke patients should be investigated for asymptomatic coronary artery disease remains matter of debate. Absolute risks of myocardial infarction (MI) and vascular death after a stroke have not been accurately assessed. We performed a systematic review and a meta-analysis to determine the risk of MI and nonstroke vascular death after transient ischemic attack (TIA) and ischemic stroke. Cohort studies of TIA or ischemic stroke patients were included if they were published between 1980 and March 2005, reported risk of MI and nonstroke vascular death, enrolled >100 patients, and had at least 1 year of follow-up. We included 39 studies in a total of 65 996 patients with mean follow-up of 3.5 years. Two reviewers independently carried out data extraction using a standardized form. Absolute annual risks were estimated through weighted meta-regressions with a random effect. To test the predictions of expected event rates derived from our analysis, we used individual patient data.
Summary of Review— The annual risks were 2.1% (CI 95%: 1.9 to 2.4) for nonstroke vascular death, 2.2% (1.7 to 2.7) for total MI, 0.9% (0.7 to 1.2) for nonfatal MI and 1.1% (0.8 to 1.5) for fatal MI. The time course of risk was linear. Estimated risks fitted well with observed risks at the individual level. There was no heterogeneity in the absolute risks according to baseline study characteristics.
Conclusions— Patients with TIA or stroke have a relatively high risk of MI and nonstroke vascular death. Additional research is needed to identify the determinants of coronary artery disease in stroke patients.
Key Words: atherosclerosis • prognosis • risk factors • cerebrovascular accident • meta-analysis • myocardial infarction • coronary disease
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Stroke and myocardial infarction (MI) share some common risk factors and pathophysiological mechanisms.1 Compared with the general population, stroke patients have an increased risk of death that notably results from MI.2 However, systematic evaluation of coronary artery disease (CAD) is not currently recommended in asymptomatic patients with a recent ischemic stroke. A recent American Heart Association and American Stroke Association statement recommends an individual risk assessment based mainly on score risk to identify patients with the highest likelihood of morbidity and mortality from unrecognized CAD after a stroke.2 However, there is no reliable estimation of the absolute risk of MI and vascular death after stroke, and high-risk populations still have to be defined. We therefore performed a systematic review and a meta-analysis of the absolute risk of MI and vascular death after stroke or transient ischemic attack (TIA). We aimed to determine overall risks, the time-course of risk, heterogeneity across studies, and any relationships between observed risk and study or population characteristics.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Search Strategy
The databases searched to obtain the articles included Pub Med of the National Library of Medicine (through March 2005) and the Cochrane database of systematic reviews (issue 4, 2004). The search strategy used both keywords and MeSH terms and took the form of (Cerebrovascular Accident or synonyms) and (Cohort Studies OR Randomized Controlled Trial) and (Coronary Arteriosclerosis or Myocardial Infarction or Vascular Death). In the Cochrane database, we studied all references from the systematic reviews related to secondary prevention of stroke. We also searched the bibliographies of all included studies and any relevant review articles for additional suitable studies. Unpublished data were not sought. Studies that recruited patients with ischemic stroke or TIA were included. Stroke/TIA had to be defined according to the World Health Organization criteria or similar. Any prospective cohort study or randomized controlled trial (RCT) was included if: (1) it was published in 1980 or later (such that computed tomography scan was used in a large proportion of patients for the diagnosis of stroke); (2) it reported on long-term follow-up of
100 patients; (3) the cohort was followed up 1 year with <5% loss to follow-up; (4) it was written in English; and (5) outcome data were reported for MI or vascular death. Articles were excluded if they included hemorrhagic strokes only, had highly selected populations (eg, single sex, young subjects, or specific race), or had patients with a specific unusual cause of stroke. Population-based studies in which a small proportion of patients had hemorrhagic strokes were not excluded. Indeed, although those studies did not provide cardiac events risks for ischemic stroke patients separately, they probably provided the most unbiased risk estimates. We carefully excluded articles that concerned patients already used in another article from the same institution, except when the methods sections made it absolutely clear that the patients did not overlap. In case of multiple publications, we chose the one most appropriate to this review, preferably the most recent.
Study Selection and Data Extraction
Two reviewers (E.T. and O.V.) independently assessed abstracts to determine eligibility and independently performed data extraction from the full articles using a predefined, standardized form. Any disagreement was resolved by discussion. We did not contact authors to clarify details or provide additional information. In one study,3 mean follow-up duration was not available, but all patients were followed up for 2 years. Therefore, we extracted events that occurred during this 2-year period.
Study Characteristics and Outcome Measures
We recorded information on the study population (community- or hospital-based cohort or RCT), proportion of TIA, sample size, prevalence of baseline traditional risk factors (hypertension and diabetes mellitus), prevalence of other atherothrombotic disease (peripheral arterial disease [PAD] and MI) at baseline, delay between stroke/TIA and inclusion in the cohort, follow-up duration, and number of deaths.
Fatal and nonfatal MI and nonstroke vascular death were considered as outcomes. Stroke was not included in vascular death. Definitions of MI and nonstroke vascular death were recorded if available. When death certificates were used only to record outcomes, the definition of those outcomes was considered not available.
Additional Data
To test the predictions of expected event rates derived from our analysis of published studies, we also used individual patient data from those studies included in the Cerebrovascular Cohort Studies Collaboration4 that were eligible for inclusion.
Data Analysis
Analyses were performed using STATA 8.0 and SAS 8.01 software packages. Because we did not have any individual data and because time to an event was generally unavailable, we were not able to use survival analysis methods. Therefore, we plotted the proportion of patients who had an outcome against the average follow-up time. We expected that the rate of nonstroke vascular events would be constant and that the scatter of points could therefore be reasonably modeled on a straight line through the origin. Metaregressions showed that for each outcome, the line of the best fit did not differ from a linear relation through the origin (ie, the P value of the intercept did not significantly differ from 0). Thus, overall annual risks and their 95% CI were estimated using weighted metaregressions with a random effect and no intercept.5,6 Residual between-trial variance was calculated using restricted maximum likelihood estimate.7 Metaregressions were also used to explore sources of heterogeneity for total MI and nonstroke vascular death outcomes. We first compared the residual between-trial variances estimated in models with follow-up duration as covariate to those estimated in models, with follow-up duration and each of the following baseline characteristics: age, percentage of patients with diabetes mellitus, previous MI, PAD, hypertension, and gender. As recommended, this comparison was not based on a statistical test.6 Second, we estimated absolute risks after having separated studies according to the prevalence of baseline risk factor prevalence using median of the whole studies as threshold (66 years of age; 63% males; 50% hypertension; 17% diabetes mellitus; 11% previous MI; and 9% PAD) and according to the cohort starting date (through 1990 versus 1990). This limit was chosen because use of statins has increased from this period.
To assess the predictive accuracy of the results, the risk of MI and nonstroke vascular death was estimated using metaregressions after exclusion of studies for which individual data were available.3,8–11 We then calculated the expected risk and their 99% CIs at the median follow-up in each individual study and graphically compared the expected and observed risks.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The 2 reviewers agreed on the inclusion/exclusion status of 87% of the abstracts reviewed, and the search resulted in 65 articles considered in detail for inclusion. Thirty-two studies were then excluded because of missing outcomes (n=26), inclusion criteria not fulfilled (n=5), and patients already included in another study (n=1). Search of bibliographies of selected studies provided 6 additional articles that fulfilled our inclusion criteria. Thus, 39 independent studies met all inclusion criteria and were included in the analysis. There were 25 RCTs,8,10–33 8 population-based cohorts,3,9,34–39 and 6 single-center hospital-based cohorts,40–45 including a total of 65 996 patients with a mean (range) follow-up of 3.5 (1–10) years (online Table available at http://stroke.ahajournals.org).
|
Incidence of MI and Nonstroke Vascular Death
The Table shows the frequency of the different outcomes and annual risks. Figure 1 shows the absolute risk of each outcome plotted against mean follow-up and the fitted regression lines. There was an overall statistically significant heterogeneity between studies in the absolute annual risk of nonstroke vascular death (
2 for heterogeneity; P<0.0001), total MI (P<0.0001), nonfatal MI (P=0.001), and fatal MI (P<0.0001). The ranges of individual annual risks were 0.4% to 3.8% for nonstroke vascular death, 0.5% to 4.7% for total MI, 0.4% to 3.2% for nonfatal MI, and 0.2% to 3.7% for fatal MI. The annual risks obtained through meta-regressions were 2.1% (95% CI, 1.9 to 2.4) for nonstroke vascular death (29 studies), 2.2% (95% CI, 1.7 to 2.7) for total MI (22 studies), 0.9% (95% CI, 0.7 to 1.2) for nonfatal MI (16 studies), and 1.1% (95% CI, 0.8 to 1.5) for fatal MI (19 studies). The absolute risk of nonstroke vascular death estimated through metaregressions was lower in studies that enrolled patients after 1990 than in those that enrolled patients before. Otherwise, metaregressions did not reveal any significant heterogeneity in the risk of total MI or nonstroke vascular death according to the baseline study characteristics (Figure 2) or for fatal MI and nonfatal MI (data not shown). The percentage of residual variance explained by the baseline characteristic covariates was low varying from 0.5% to 7.0% depending on the covariate. In studies specifically devoted to patients with TIA or stroke attributable to atherosclerosis,10,11,13,15,19,32 the risk of MI (4 studies) was 1.9% per year (95% CI, not estimable) and that of nonstroke vascular death (5 studies) 2.3% per year (95% CI, 1.9 to 2.7) ie, not different from the risks derived from the other studies. Nonstroke vascular death risk did not differ between RCTs and population-based studies (Figure 2). Pooled risk of total MI could not be estimated in population-based cohorts because only one study was available for this outcome.9 Similarly, vascular death and total MI outcomes were each available in only 2 hospital-based studies, not allowing metaregressions.16,42–44
|
|
|
Predicted and Observed Risks
After exclusion of studies for which individual data were available, annual risks estimated by metaregressions were 2.1% (95% CI, 1.8 to 2.4) for nonstroke vascular death, 2.3% (95% CI, 1.6 to 2.9) for total MI, 1.0% (95% CI, 0.7 to 1.2) for nonfatal MI, and 1.1% (95% CI, 0.7 to 1.5) for fatal MI. Figure 3 shows predicted versus observed risks of these events at median follow-up in studies with individual data. The estimated values were reasonably close to the absolute risk of nonfatal MI and nonstroke vascular death but slightly overestimated that of fatal and total MI.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The main result of this meta-analysis is that after a stroke or a TIA, the risks of MI and nonstroke vascular death are each
2% per year. Such risks are usually considered high absolute risks in different guidelines for assessment of cardiovascular risk.46,47 Estimates obtained through metaregressions using a large number of studies including community- and hospital-based populations fitted well with those observed at the individual level, except for fatal and total MI, for which our prediction tended to overestimate the risk. In fact, the definition of fatal MI varied according to studies, notably because sudden deaths were inconstantly considered fatal MI. Conversely, the definition of nonfatal MI was consistent between studies, being based on clinical data, ECG changes, and cardiac enzyme elevation.
Whether stroke patients should be investigated for asymptomatic CAD remains a matter of debate.2 The relevance of coronary investigations strongly depends on the prevalence of asymptomatic CAD, the spontaneous risk of coronary events, and the feasibility of preventive therapeutics. Small studies have suggested that 25% to 60% of stroke patients without any clinical CAD may have silent myocardial ischemia on noninvasive tests,2 and one study found that about one third of patients (including stroke patients) evaluated before carotid surgery had 1 coronary artery stenosis 70%.48 Although we showed that the risk of coronary events after a stroke is relatively high, many patients will not have such events. It is therefore essential to determine highest-risk patients, who will benefit most from CAD screening. We found a significant heterogeneity across studies; however, baseline characteristics of the populations, including age, gender, and prevalence of diabetes mellitus, hypertension, previous MI, or PAD, were not correlated with the absolute risk of MI or nonstroke vascular death. This finding could be explained by the low power of metaregressions to detect heterogeneity sources.5 We may also speculate that after stroke, the risk of severe coronary events is not related solely to the presence of risk factors. These results are in agreement with the Framingham cohort, in which the number of factors associated with an increased risk of CAD was lower in patients with previous CAD or stroke than in those free of cardiovascular disease.49 Therefore, it remains unknown whether classical risk scores accurately predict risk of MI and nonstroke vascular death after a stroke.46,47 Other characteristics such as cause of stroke and severity of atherosclerotic disease may play a more important role in the prediction of subsequent coronary events. Although MI is invariably caused by atherosclerosis, stroke may result from various causes. Depending on its definition, atherosclerosis explains 20% to 40% of strokes.50 There are several arguments suggesting that patients with stroke related to atherosclerosis are at higher risk of MI or nonstroke vascular death than are patients with nonatherosclerotic subtypes. First, anatomical studies have shown a correlation between the extent and the severity of atherosclerosis in carotid or vertebral arteries and in coronary arteries.51,52 Second, asymptomatic carotid artery stenosis is an independent risk factor for CAD.53 Third, cross-sectional studies have suggested that the prevalence and the severity of asymptomatic CAD increase in case of stroke attributable to large artery disease and with the severity of carotid artery stenosis.2 Finally, it has been shown that patients with stroke attributable to large artery atherosclerotic disease have a higher risk of death than those with strokes attributable to small vessel disease or of unknown origin,2,36,38,50,54,55 although cardiac causes were not always individualized in those studies. In this meta-analysis, because individual data were not available, patients with stroke attributable to atherosclerosis could not be analyzed separately. In studies specifically devoted to strokes related to intracranial or carotid artery atherosclerosis, the risk of MI or nonstroke vascular death did not differ from that found in other studies. Nevertheless, those studies were scarce and included patients with heterogeneous severity of atherosclerosis ranging from plaques to severe stenosis.
Surprisingly, we did not find any positive correlation between diabetes mellitus prevalence at baseline and risk of MI during follow-up. The common association between diabetes mellitus and small vessel disease, which seems to carry a low risk of cardiac events,45 may partly explain this finding. Similarly, in the MATCH trial, which enrolled an important proportion (68%) of diabetic patients, the risk of total MI was only 1.2% per year.28 Atherosclerosis and cerebral small vessel disease share common risk factors, but their pathophysiology is different. It is possible that patients who develop small vessel cerebral disease are not particularly prone to develop CAD because of other inherited or acquired characteristics.
Although the time course of the risk of each outcome seems to be linear over a 5-year period, we cannot rule out a higher early risk of cardiac events because patients were generally included several weeks to months after their initial event. Similarly, the very long-term risk remains not well estimated because all the major studies had an average follow-up ranging from 2 to 4 years. Nevertheless, short-term risk assessment is most valuable when aiming to reinforce secondary prevention.
The present systematic review is subject to several limitations. First, we were not able to estimate the risk of MI and nonstroke vascular death in patients without any previous clinical CAD at the time of stroke because those patients were not analyzed separately in studies selected here. Only a meta-analysis on individual data would allow such an analysis. Nevertheless, the proportion of patients with previous symptomatic CAD at baseline was relatively low (median 11%; range 2% to 27%), and we did not find any correlation between that proportion and the subsequent risk of MI or nonstroke vascular death. Second, metaregressions have several well-known methodological limitations, including lack of power to explain heterogeneity and risk of ecological and confounding biases.5 Even if metaregressions were undertaken correctly from a technical point of view, relationships with averages of patients’ characteristics are potentially misleading.56 Indeed, the relationship between risks and patients’ characteristics across the studies may not be the same as the relationships within trials. Therefore, our findings should be interpreted with caution. However, only metaregressions were feasible with continuous variables such as an absolute risk. Third, our systematic review mainly included RCTs and quite old population-based studies. Although RCTs tend to recruit healthier patients and may underestimate risk of MI and nonstroke vascular death, they were the best available source of data for the present review. Conversely, treatments were heterogeneous in RCTs. Patients included in the most recent trials were most often treated with antithrombotic therapies and other agents, such as lipid-lowering agents and angiotensin-converting inhibitors, that lower the risk of MI as well as stroke and are theoretically more representative of the current practice than those included in old trials. Indeed, in our review, risk of nonstroke vascular death was lower in studies that had enrolled patients after 1990 than in those performed before. However, this result was not observed for MI, and the number of studies that had enrolled patients after 1990 is low. In addition, in practice, many patients do not receive optimal prevention according to guidelines and results of RCTs.57
The high risk of MI and nonstroke vascular death in stroke patients should urge us to improve secondary prevention. Several strategies can be considered. First, a widespread reinforcement of all medical preventive measures without CAD screening. Second, a systematic screening of asymptomatic coronary lesions requiring specific treatments. Third, a selective screening based on risk stratification. Indeed, screening could potentially improve prognosis because several studies suggest that medical treatment (eg, ß-blockers) or revascularization (coronary artery bypass surgery or angioplasty) alter prognosis in patients with silent ischemia beyond risk factor reduction.2,58 More research is needed to identify the determinants of the CAD risk and to assess the best strategy to decrease cardiac morbidity and mortality in stroke patients.2
|
Acknowledgments |
|---|
This study was supported in part by the Institut de l’Athérothrombose, Sanofi-Aventis and Bristol-Myers-Squibb pharmaceuticals, which had no role in the analysis or interpretation of the data or in the decision to publish this manuscript. We thank the Cerebrovascular Cohort Studies Collaboration for access to data.
Received June 27, 2005; revision received September 12, 2005; accepted September 22, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Pasternak RC, Criqui MH, Benjamin EJ, Fowkes FG, Isselbacher EM, McCullough PA, Wolf PA, Zheng ZJ. Atherosclerotic Vascular Disease Conference: Writing Group I: Epidemiology. Circulation. 2004; 109: 2605–2612.
2. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, Taubert KA. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation. 2003; 108: 1278–1290.
3. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993; 24: 786–800.
4. Ariesen MJ, Algra A, Warlow CP, Rothwell PM; Cerebrovascular Cohort Studies Collaboration. Prognostic factors of primary intracerebral hemorrhage risk in patients after an episode of cerebral ischemia. J Neurol Neurosurg Psychiatry. In press.
5. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002; 21: 1559–1573.[CrossRef][Medline] [Order article via Infotrieve]
6. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002; 21: 589–624.[CrossRef][Medline] [Order article via Infotrieve]
7. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999; 18: 2693–2708.[CrossRef][Medline] [Order article via Infotrieve]
8. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991; 54: 1044–1054.
9. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke. 1990; 21: 848–853.
10. Gates PC, Eliasziw M, Algra A, Barnett HJM, Gunton RW; North American Symptomatic Carotid Endarterectomy Trial Group. Identifying patients with symptomatic carotid artery disease at high and low risk of severe myocardial infarction and cardiac death. Stroke. 2002; 33: 2413–2416.
11. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet. 2000; 355: 19–24.[CrossRef][Medline] [Order article via Infotrieve]
12. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. 1983; 14: 5–14.
13. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke. 1983; 14: 15–22.
14. Persantine Aspirin Trial in Cerebral Ischemia. Part II: endpoint results. The American-Canadian Cooperative Study Group. Stroke. 1985; 16: 406–415.
15. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomised trial. N Engl J Med. 1985; 313: 1191–1200.[Abstract]
16. Eriksson SE. Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neurol Scand. 1985; 71: 485–493.[Medline] [Order article via Infotrieve]
17. Gent M, Blakely JA, Hachinski V, Roberts RS, Barnett HJ, Bayer NH, Carruthers SG, Collins SM, Gawel MG, Giroux-Klimek M. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke. 1985; 16: 416–424.
18. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke. 1987; 18: 325–334.
19. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke. 1988; 19: 1211–1215.
20. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989; 321: 501–507.[Abstract]
21. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1: 1215–1220.[Medline] [Order article via Infotrieve]
22. ESPS Group. European Stroke Prevention Study. Stroke. 1990; 21: 1122–1130.
23. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991; 338: 1345–1349.[CrossRef][Medline] [Order article via Infotrieve]
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329–1339.[CrossRef][Medline] [Order article via Infotrieve]
25. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143: 1–13.[CrossRef][Medline] [Order article via Infotrieve]
26. Ito E, Takahashi A, Yamamoto H, Kuzuhara S, Uchiyama S, Nakajima M. Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. Intern Med. 2003; 42: 793–799.[Medline] [Order article via Infotrieve]
27. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T, Tong DC. Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Can aspirin ever be surpassed for stroke prevention? Stroke. 2003; 34: 840–848.
28. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331–337.[CrossRef][Medline] [Order article via Infotrieve]
29. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004; 363: 757–767.[CrossRef][Medline] [Order article via Infotrieve]
30. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology. 2004; 62: 1073–1080.
31. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc. 2004; 291: 565–575.
32. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005; 352: 1305–1316.
33. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033–1041.[CrossRef][Medline] [Order article via Infotrieve]
34. Howard G, Evans GW, Murros KE, Toole JF, Lefkowitz D, Truscott BL. Cause specific mortality following cerebral infarction. J Clin Epidemiol. 1989; 42: 45–51.[CrossRef][Medline] [Order article via Infotrieve]
35. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000; 31: 2080–2086.
36. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology. 1998; 50: 208–216.
37. Loor HI, Groenier KH, Limburg M, Schuling J, Meyboom-de Jong B. Risks and causes of death in a community-based stroke population: 1 month and 3 years after stroke. Neuroepidemiology. 1999; 18: 75–84.[CrossRef][Medline] [Order article via Infotrieve]
38. Hartmann A, Rundek T, Mast H, Paik MC, Boden-Albala B, Mohr JP, Sacco RL. Mortality and causes of death after first ischemic stroke. The Northern Manhattan Stroke Study. Neurology. 2001; 57: 2000–2005.
39. Terent A. Cerebrovascular mortality 10 years after stroke: a population-based study. Stroke. 2004; 35: E343–E345.[Medline] [Order article via Infotrieve]
40. Olsson JE, Brechter C, Backlund H, Krook H, Muller R, Nitelius E, Olsson O, Tornberg A. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke. 1980; 11: 4–9.
41. Simonsen N, Christiansen HD, Heltberg A, Marquardsen J, Pedersen HE, Sorensen PS. Long-term prognosis after transient ischemic attacks. Acta Neurol Scand. 1981; 63: 156–168.[Medline] [Order article via Infotrieve]
42. Muuronen A, Kaste M. Outcome of 314 patients with transient ischemic attacks. Stroke. 1982; 13: 24–31.[Abstract]
43. Carolei A, Candelise L, Fiorelli M, Francucci BM, Motolese M, Fieschi C. Long-term prognosis of transient ischemic attacks and reversible ischemic neurologic deficits: a hospital-based study. Cerebrovasc Dis. 1992 ;2: 272.
44. Falke P, Lindgärde F, Stavenow L. Prognostic indicators for mortality in transient ischemic attack and minor stroke. Acta Neurol Scand. 1994; 90: 78–82.[Medline] [Order article via Infotrieve]
45. Salgado AV, Ferro JM, Gouveia-Oliveira A. Long-term prognosis of first-ever lacunar strokes. A hospital-based study. Stroke. 1996; 27: 661–666.
46. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999; 100: 1481–1492.
47. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 1998; 19: 1434–1503.
48. Hertzer NR, Young JR, Beven EG, Graor RA, O’Hara PJ, Ruschhaupt WF, deWolfe VG, Maljovec LC. Coronary angiography in 506 patients with extracranial cerebrovascular disease. Arch Intern Med. 1985; 145: 849–852.
49. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J. 2000; 139: 272–281.[Medline] [Order article via Infotrieve]
50. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001; 32: 2559–2566.
51. Mathur KS, Kashyap SK, Kumar V. Correlation of the extent and severity of atherosclerosis in the coronary and cerebral arteries. Circulation. 1963; 27: 929–934.
52. Solberg LA, McGarry PA, Moossy J, Strong JP, Tejada C, Löken AC. Severity of atherosclerosis in cerebral arteries, coronary arteries, and aortas. Ann N Y Acad Sci. 1968; 149: 956–973.[Medline] [Order article via Infotrieve]
53. Joakimsen O, Bonaa KH, Mathiesen EB, Stensland-Bugge E, Arnesen E. Prediction of mortality by ultrasound screening of a general population for carotid stenosis: the Tromso Study. Stroke. 2000; 31: 1871–1876.
54. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001; 32: 2735–2740.
55. Longstreth WT Jr, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology. 2001; 56: 368–375.
56. Thompson SG, Higgins JP. Can meta-analysis help target interventions at individuals most likely to benefit? Lancet. 2005; 365: 341–346.[Medline] [Order article via Infotrieve]
57. Holloway RG, Benesch C, Rush SR. Stroke prevention. Narrowing the evidence-practice gap. Neurology. 2000; 54: 1899–1906.
58. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, Gott JP, Herrmann HC, Marlow RA, Nugent W, O’Connor GT, Orszulak TA, Rieselbach RE, Winters WL, Yusuf S, Gibbons RJ, Alpert JS, Garson A Jr, Gregoratos G, Russell RO, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation. 1999; 100: 1464–1480.
This article has been cited by other articles:
 |
|
 |
|
  P. Armario and A. de la Sierra Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents? Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 197 - 204. [Abstract] [PDF]
|
|
|
|
 |
|
 C. S. Roberts, P. B. Gorelick, X. Ye, C. Harley, and G. A. Goldberg Additional Stroke-Related and Non-Stroke-Related Cardiovascular Costs and Hospitalizations in Managed-Care Patients After Ischemic Stroke Stroke, April 1, 2009; 40(4): 1425 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weimar, H.-C. Diener, M. J. Alberts, P. G. Steg, D. L. Bhatt, P. W.F. Wilson, J.-L. Mas, J. Rother, and on behalf of the REACH Registry Investigators The Essen Stroke Risk Score Predicts Recurrent Cardiovascular Events: A Validation Within the REduction of Atherothrombosis for Continued Health (REACH) Registry Stroke, February 1, 2009; 40(2): 350 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco and P. G. Steg Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention Eur. Heart J., July 1, 2008; 29(13): 1605 - 1607. [Full Text] [PDF]
|
|
|
|
 |
|
 C Sudlow Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management Practical Neurology, June 1, 2008; 8(3): 141 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, J. Coste, M. Voicu, J. Kansao, R. Masmoudi, B. Doumenc, P. Durieux, and J.-L. Mas Importance of In-Hospital Initiation of Therapies and Therapeutic Inertia in Secondary Stroke Prevention: IMplementation of Prevention After a Cerebrovascular evenT (IMPACT) Study Stroke, June 1, 2008; 39(6): 1834 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. V. Elkind Prognosis of Transient Neurological Attacks JAMA, April 16, 2008; 299(15): 1771 - 1771. [Full Text] [PDF]
|
|
|
|
 |
|
 J R Selvarajah, C J Smith, S Hulme, R F Georgiou, A Vail, P J Tyrrell, and on behalf of the NORTHSTAR Collaborators Prognosis in patients with transient ischaemic attack (TIA) and minor stroke attending TIA services in the North West of England: The NORTHSTAR Study J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 38 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, O. Varenne, and J.-L. Mas Overestimation of Coronary Risk in Stroke Patients Stroke, October 1, 2007; 38(10): e98 - e98. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Dhamoon and M. S.V. Elkind Response to Letter by Touze et al Stroke, October 1, 2007; 38(10): e99 - e99. [Full Text] [PDF]
|
|
|
|
|
|
J. Prosser, L. MacGregor, K. R. Lees, H.-C. Diener, W. Hacke, S. Davis, and on behalf of the VISTA Investigators Predictors of Early Cardiac Morbidity and Mortality After Ischemic Stroke Stroke, August 1, 2007; 38(8): 2295 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hackam and J. D. Spence Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study Stroke, June 1, 2007; 38(6): 1881 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Ph. G. Steg, D. L. Bhatt, P. W. F. Wilson, R. D'Agostino Sr, E. M. Ohman, J. Rother, C.-S. Liau, A. T. Hirsch, J.-L. Mas, Y. Ikeda, et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis JAMA, March 21, 2007; 297(11): 1197 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Brown, F. Al-Senani, L. D. Lisabeth, M. A. Farnie, L. A. Colletti, K. M. Langa, A. M. Fendrick, N. M. Garcia, M. A. Smith, and L. B. Morgenstern Defining Cause of Death in Stroke Patients: The Brain Attack Surveillance in Corpus Christi Project Am. J. Epidemiol., March 1, 2007; 165(5): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, C. P. Warlow, and P. M. Rothwell Risk of Coronary and Other Nonstroke Vascular Death in Relation to the Presence and Extent of Atherosclerotic Disease at the Carotid Bifurcation Stroke, December 1, 2006; 37(12): 2904 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Additional articles abstracted in ACP Journal Club Evid. Based Med., August 1, 2006; 11(4): 126 - 126. [Full Text] [PDF]
|
|
|
|
|
|
H. Arima, C. Tzourio, K. Butcher, C. Anderson, M.-G. Bousser, K. R. Lees, J. L. Reid, T. Omae, M. Woodward, S. MacMahon, et al. Prior Events Predict Cerebrovascular and Coronary Outcomes in the PROGRESS Trial Stroke, June 1, 2006; 37(6): 1497 - 1502. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||